EBS
HealthcareEmergent BioSolutions Inc.
$12.85
+$0.34 (+2.72%)
Jan 5, 2026
Price History (1Y)
Analysis
Emergent BioSolutions Inc. is a healthcare company operating in the specialty and generic drug manufacturers industry within the sector of Healthcare. The company has a market capitalization of $685.56 million, annual revenues of $788.90 million, and employs approximately 900 individuals. The company's financial health indicates moderate profitability, with gross margins of 48.7%, operating margins of 37.8%, and profit margins of 9.6%. Return on equity is at 13.9% and return on assets is at 5.3%. The balance sheet shows a debt-to-equity ratio of 115.19, indicating significant leverage, and a current ratio of 5.76, suggesting manageable liquidity. The company's valuation metrics are notable, with a price-to-earnings (P/E) ratio of 9.45 and forward P/E of 4.30, indicating relatively low expectations for future earnings growth compared to its trailing twelve-month earnings. The revenue growth rate is at -21.3% year-over-year, while the earnings growth rate is at -55.8%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Visit website →Key Statistics
- Market Cap
- $685.56M
- P/E Ratio
- 9.45
- 52-Week High
- $13.41
- 52-Week Low
- $4.02
- Avg Volume
- 1.04M
- Beta
- 2.31
Company Info
- Exchange
- NYQ
- Country
- United States
- Employees
- 900